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Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous dis-
ease, and it’s associated with an increased use of various
biological agents in recent years.
Aim
Evaluate clinical response to current biological agent in
JIA patients.
Methods
This is a retrospective study of 109 JIA patients from a
tertiary centre (see poster 1). Variables included were:
current biological treatment (both the first agent used as
the second, third or fourth when it had been switched)
and duration of treatment (years with a new agent or
since reintroduction of an agent used before) plus physi-
cian visual analogue scale (ph-VAS), erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP) at
baseline and at the end of the study. Concomitant ther-
apy with methotrexate (MTX) was also recorded.
Results
Duration of treatment with the current biological agent
was 1.2 ± 1 (0.1- 4.9) median 0.8 years. This agent was
etanercept (ETA) in 58 cases, adalimumab (ADA) in 16,
tocilizumab (TCZ) in 11, anakinra (AK) in 9 and inflixi-
mab (IFX) in 2. Thirteen patients were off treatment
with biological agents, 12 due to inactive disease and
one because of inefficacy.
Concomitant treatment with MTX was observed in 8/
58 (14%) patients with ETA, 4/16 (25%) with ADA, 5/11
(46%) with TCZ, 1/2 (50%) with IFX and none with AK.
Table 1.
Conclusion
The results indicate that reintroduction of a previously
effective biological agent may be successful; besides,
switching to a second, third or even fourth biological
agent in those patients whose disease remains active,
can be effective as well.
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Table 1 Analytical and clinical response to current biological agent
Ph-VAS ESR CRP
Initial* End* ۵ p Initial* End* ۵ p Initial* End* ۵ p
ETA 3.25 0.5 -6 0.00 28 12 -5 0.00 13.2 2.3 -5 0.00
ADA 2.42 0.4 -3 0.01 17 13 -1 0.26 5.58 1.2 -2 0.06
AK 5.36 0.00 -3 0.01 62 9 -2 0.02 69.5 2.9 -2 0.03
TCZ 6.45 0.86 -3 0.01 46 4 -3 0.01 95.6 0.6 -3 0.01
IFX 4.9 0.00 47 6 32.8 0.9
*Values are expressed as mean.
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